The study of dissolution kinetics of drugs in the form of tablets with riboxinum (inosine) has been carried out in accordance with the requirements of the “biowaiver” procedure, the recommendations of the SPhU and the WHO requirements in order to assess the possibility of replacing the pharmacokinetic studies in vivo by tests in vitro. The possibility to use the recommendations of the "biowaiver" procedure for the registration of generics with riboxinum has been found.
Select your language of interest to view the total content in your interested language
Der Pharma Chemica received 15261 citations as per Google Scholar report